ImmunityBio (IBRX) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 09, 2016
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	NK
Entity Registrant Name	NANTKWEST, INC.
Entity Central Index Key	1,326,110
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		82,311,764

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 38,223	$ 175,908
Receivables, net, prepaid expenses and other current assets	4,196	3,322
Marketable securities	175,540	118,310
Total current assets	217,959	297,540
Marketable securities, noncurrent	107,933	55,135
Property and equipment, net	9,507	5,523
Intangible assets, net	6,396	7,292
Other assets	1,140	1,359
Total assets	342,935	366,849
Current liabilities:
Accounts payable	3,303	2,085
Accrued expenses	4,724	2,575
Due to related parties	1,727	1,352
Other current liabilities	291	136
Total current liabilities	10,045	6,148
Build-to-suit liability, less current portion	2,417	2,468
Deferred rent	1,924	845
Deferred revenue	197	228
Deferred tax liability	969	1,165
Other liabilities	26
Total liabilities	15,578	10,854
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock	8	8
Additional paid-in capital	651,330	606,555
Accumulated other comprehensive income (loss)	424	(192)
Accumulated deficit	(324,405)	(250,376)
Total stockholders’ equity	327,357	355,995
Total liabilities and stockholders’ equity	$ 342,935	$ 366,849

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - Common Stock Class Undefined - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	81,770,436	81,311,686
Common stock, shares outstanding	81,770,436	81,311,686

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue	$ 12	$ 91	$ 18	$ 211
Operating expenses:
Research and development	6,389	2,074	11,344	2,677
Selling, general and administrative	28,588	128,412	55,255	160,030
Total operating expenses	34,977	130,486	66,599	162,707
Loss from operations	(34,965)	(130,395)	(66,581)	(162,496)
Other income (expense):
Investment income, net	739	33	1,507	65
Change in fair value of warrant liability		(483)		(1,366)
Other income (expense), net	1	(48)	29	56
Total other income (expense)	740	(498)	1,536	(1,245)
Loss before income taxes	(34,225)	(130,893)	(65,045)	(163,741)
Income tax (benefit) expense, net	(228)		(371)	1
Net loss	$ (33,997)	$ (130,893)	$ (64,674)	$ (163,742)
Net loss per share:
Basic and diluted	$ (0.41)	$ (1.99)	$ (0.79)	$ (2.58)
Weighted average number of shares during the period:
Basic and diluted	81,959,248	65,789,041	81,769,964	63,450,609

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (33,997)	$ (130,893)	$ (64,674)	$ (163,742)
Other comprehensive income, net of income taxes:
Net unrealized gain on available-for-sale securities	129		646
Reclassification of net realized gains on available-for-sale securities included in net loss	(23)		(30)
Total other comprehensive income	106		616
Comprehensive loss	$ (33,891)	$ (130,893)	$ (64,058)	$ (163,742)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2015	$ 355,995	$ 8	$ 606,555	$ (192)	$ (250,376)
Beginning Balance, Shares at Dec. 31, 2015		81,311,686
Exercise of stock options	818		818
Exercise of stock options, Shares		1,642,264
Stock-based compensation expense	43,917		43,917
Vesting of restricted stock units		24,166
Employee payroll taxes withheld related to vesting of restricted stock units	(32)		(32)
Employee payroll taxes withheld related to vesting of restricted stock units, Shares		(4,152)
Exercise of warrants	41		41
Exercise of warrants, Shares		25,072
Change in accounting principle - ASU 2016-09 forfeiture adjustment			31		(31)
Repurchase of common stock	$ (9,324)				(9,324)
Repurchase of common stock, Shares	(1,228,600)	(1,228,600)
Other comprehensive income, net	$ 616			616
Net loss	(64,674)				(64,674)
Ending Balance at Jun. 30, 2016	$ 327,357	$ 8	$ 651,330	$ 424	$ (324,405)
Ending Balance, Shares at Jun. 30, 2016		81,770,436

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities:
Net loss	$ (64,674)	$ (163,742)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	998	986
Stock-based compensation expense	43,917	150,836
Deferred income tax benefit	(373)
Change in value of warrant liability		1,366
Non-cash interest items	(516)
Loss incurred by Inex Bio		57
Loss on disposal of assets	18
Amortization of net premiums on marketable securities	943
Gain on sales of marketable securities	(69)
Gain on settlement of note payable		(133)
Changes in operating assets and liabilities:
Accounts receivable	(3)	100
Prepaid and other current assets	(355)	(300)
Other assets	(162)	(3,592)
Accounts payable	84	2,048
Accrued expenses and other liabilities	1,638	2,312
Due to related parties	375
Deferred rent	1,031
Deferred revenue	(9)	(100)
Net cash used in operating activities	(17,157)	(10,162)
Investing activities:
Purchases of property and equipment	(2,123)	(152)
Purchase of Inex Bio Inc., net of cash acquired		(1,818)
Investment in intangible assets		483
Purchases of marketable securities	(165,837)
Sales/maturities of marketable securities	55,897
Net cash used in investing activities	(112,063)	(2,453)
Financing activities:
Proceeds from debt and equity offerings, net of issuance costs		70,976
Payments on notes payable		(132)
Proceeds from exercise of stock options	818	768
Proceeds from exercise of warrants	41	7,134
Repurchase of common stock	(9,324)	(4,798)
Net cash (used in) provided by financing activities	(8,465)	73,948
Net decrease in cash and cash equivalents	(137,685)	61,333
Cash and cash equivalents, beginning of period	175,908	59,104
Cash and cash equivalents, end of period	38,223	120,437
Cash paid during the period for:
Income taxes	1	1
Supplemental disclosure of non-cash investing and financing activities:
Estimated fair value of building under build-to-suit lease		2,740
Lease Incentive	50
Property and equipment purchases included in accounts payable and accrued expenses	2,059
Cashless exercise of stock options and warrants	456	966
Unrealized gain on marketable securities	$ 962
Inex Bio Inc
Supplemental disclosure of non-cash investing and financing activities:
Issuance of warrants in Inex Bio, Inc. acquisition		$ 5,170

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization NantKwest, Inc. (the Company) was incorporated in Illinois on October 7, 2002 under the name ZelleRx Corporation. On January 22, 2010, the Company changed its name to Conkwest, Inc., and on July 10, 2015, the Company changed its name to NantKwest, Inc. In March 2014, the Company redomesticated from the State of Illinois to the State of Delaware and the Illinois Company ceased to exist. The Company is a biotechnology company headquartered in San Diego, California with certain operations in Culver City, California and Woburn, Massachusetts. The Company is commercially developing targeted direct-acting immunotherapeutic agents for a variety of clinical conditions. The Company holds the exclusive right to commercialize activated natural killer (aNK) cells, a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells. The Company owns corresponding U.S. and foreign composition and methods-of-use patents and applications covering the clinical use of aNK cells as a therapeutic to treat a spectrum of clinical conditions. The Company also licensed exclusive commercial rights to a portfolio of CD16 bearing aNK cells along with the corresponding U.S. and foreign composition and methods-of-use patents and applications covering the non-clinical use in laboratory testing of monoclonal antibodies as well as clinical use as a therapeutic to treat cancers in combination with antibody products. The Company has licensed or sub-licensed its cell lines and intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses. The Company retains exclusive worldwide rights to clinical and research data, intellectual property and know-how developed with the Company’s aNK cells, as well as the only clinical grade master cell bank. Unaudited Interim The accompanying condensed consolidated balance sheet at June 30, 2016, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2016, the condensed consolidated statements of cash flows for the six months ended June 30, 2016, and the condensed consolidated statement of stockholders’ equity for the six months ended June 30, 2016, have been prepared by management of the Company and have not been audited. These financial statements have been prepared on the same basis as the audited consolidated financial statements for the fiscal year ended December 31, 2015 and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the Company’s results for the periods presented. These financial statements should be read in conjunction with the financial statements and notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (GAAP). Principles of Consolidation The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc., and have been prepared in accordance with GAAP. All intercompany amounts have been eliminated. Prior Restatement The Company identified material errors in stock compensation expense, property and equipment and build-to-suit liability balances along with various other immaterial errors during the fourth quarter of fiscal 2015 related to prior periods. The correction of these errors resulted in the restatement of previously reported unaudited condensed consolidated financial statements for the second and third quarters of fiscal 2015, which were included in the Annual Report on Form 10-K for the year ended December 31, 2015. Accordingly, within this Quarterly Report on Form 10-Q, the unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2015 and the unaudited condensed consolidated statement of cash flows for the six months ended June 30, 2015 have been labeled Restated. Liquidity As of June 30, 2016, the Company had an accumulated deficit of approximately $324.4 million. The Company also had negative cash flow from operations of approximately $17.2 million during the six months ended June 30, 2016. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents and marketable securities on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents and marketable securities will enable it to fund operations and capital expenditure requirements for the foreseeable future, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies With the exception of the preclinical and clinical trial accrual, stock repurchases and stock-based compensation policies discussed below, there have been no significant changes to the items that the Company disclosed as its summary of significant accounting policies in the Annual Report on Form 10-K for the year ended December 31, 2015. Preclinical and As part of the process of preparing the financial statements, the Company is required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company estimates clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on the Company’s behalf. In accruing clinical and research related fees, the Company estimates the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Stock Repurchases In November 2015, the board of directors approved a share repurchase program (2015 Share Repurchase Program) allowing the CEO or CFO, on behalf of the Company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0 million of the Company’s outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases will be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company expects to finance the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, the Company has elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, the Company will allocate the excess value to accumulated deficit. Stock-Based Compensation The Company implemented Financial Accounting Standards Board issued Accounting Standard Update 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, preclinical and clinical trial accruals, and the valuation of build-to-suit lease assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of June 30, 2016 2015 Outstanding options 7,064,002 8,447,209 Outstanding restricted stock units 1,424,772 — Outstanding warrants 17,794,544 18,417,078 Total 26,283,318 26,864,287 Amounts in the table above reflect the common stock equivalents of the noted instruments. Recent Accounting Pronouncements In February 2016, the FASB issued or ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The Company has adopted the guidance to 1) account for stock-based award forfeitures as they occur rather than apply an estimated forfeiture rate, 2) recognize the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid-in capital pools, 3) repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, and 4) elected to adopt the amendments related to the presentation of excess tax benefits on the statement of cash flows using a prospective transition method.

Financial Statement Details

Financial Statement Details	6 Months Ended
	Jun. 30, 2016
Financial Statement Details [Abstract]
Financial Statement Details	3. Financial Statement Details Receivables, Net, Prepaid Expenses and Other Current Assets As of June 30, 2016 and December 31, 2015, receivables, net, prepaid expenses and other current assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Prepaid services $ 1,537 $ 631 Interest receivable - marketable securities 1,428 911 Prepaid license fees 475 101 Prepaid legal fees 350 350 Deposits 141 — Due from related parties (Note 7) 121 217 Prepaid insurance 84 466 Prepaid rent 46 — Accounts receivable, net 3 — Tax refund receivable — 646 Other 11 — $ 4,196 $ 3,322 Property and Equipment, Net As of June 30, 2016 and December 31, 2015, property and equipment consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Construction in progress $ 7,825 $ 5,136 Equipment 1,021 241 Software 400 6 Leasehold improvements 356 182 Furniture & fixtures 175 125 9,777 5,690 Accumulated depreciation (270 ) (167 ) $ 9,507 $ 5,523 Construction in progress includes the estimated fair market value of the building under the Company’s build-to-suit lease for $2.7 million of which the Company is the "deemed owner" for accounting purposes only. See Note 7. Intangible Assets As of June 30, 2016 and December 31, 2015, intangible assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Technology license* $ 8,636 $ 8,636 Less accumulated amortization (2,240 ) (1,344 ) $ 6,396 $ 7,292 *Inclusive of $1.5 million intangible asset related to the deferred tax liability, which is not amortized. Amortization expense was $0.5 million, and $0.4 million for the three months ended June 30, 2016 and 2015, respectively, and $0.9 million and $0.4 million for the six months ended June 30, 2016 and 2015, respectively. Amortization for the Company’s technology license is included in research and development expense in the condensed consolidated statement of operations. Other Assets As of June 30, 2016 and December 31, 2015, other assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Equipment not placed in service $ 567 $ 624 License fees 308 — Security deposit 248 344 Software license and implementation costs 17 391 $ 1,140 $ 1,359 Accrued Expenses As of June 30, 2016 and December 31, 2015, accrued expenses consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Accrued bonus $ 2,179 $ 1,359 Accrued professional and service fees 616 367 Accrued construction costs 610 132 Accrued compensation 590 348 Accrued preclinical and clinical trial costs 449 — Accrued trade shows 109 — Accrued franchise and property taxes 39 225 Other 132 144 $ 4,724 $ 2,575 Investment Income, Net Net investment income includes interest income from all bank accounts as well as marketable securities, net realized gains or losses on sales of investments and the amortization of the premiums and discounts of the investments and is as follows for the three and six months ended June 30, 2016 and 2015 (in thousands). Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Interest income $ 1,239 $ 33 $ 2,431 $ 65 Investment amortization accretion expense, net (516 ) — (942 ) — Net realized gains on investments 16 — 18 — $ 739 $ 33 $ 1,507 $ 65 Interest income includes interest from the Company’s bank deposits. The Company did not recognize an impairment loss on any investments for the three and six months ended June 30, 2016 and 2015.

Cash Equivalents and Marketable

Cash Equivalents and Marketable Securities	6 Months Ended
	Jun. 30, 2016
Cash Equivalents And Marketable Securities [Abstract]
Cash Equivalents and Marketable Securities	4. Cash Equivalents and Marketable Securities As of June 30, 2016, all of the Company’s marketable securities are classified as available-for-sale and are scheduled to mature within 4.0 years. At June 30, 2016, the detail of the Company’s cash equivalents and marketable securities is as follows (in thousands): June 30, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current: Commercial paper $ 4,993 $ 4 $ — $ 4,997 Government sponsored securities 21,384 32 — 21,416 Corporate debt securities 138,173 80 (17 ) 138,236 Foreign government bonds 10,880 13 (2 ) 10,891 Current portion 175,430 129 (19 ) 175,540 Noncurrent: Government sponsored securities 27,022 166 — 27,188 Corporate debt securities 80,241 510 (6 ) 80,745 Noncurrent portion 107,263 676 (6 ) 107,933 Total $ 282,693 $ 805 $ (25 ) $ 283,473 At June 30, 2016, 29 of the securities and bonds are in an unrealized loss position. No securities have been in an unrealized loss position for greater than 12 months. Available-for-sale investments that had been in an unrealized loss position for less than 12 months at June 30, 2016 are as follows (in thousands): June 30, 2016 Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 60,926 $ (23 ) Foreign government bonds 1,864 (2 ) Total $ 62,790 $ (25 ) The Company evaluated its securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Therefore, the Company did not recognize any other-than-temporary impairment loss during the three and six months ended June 30, 2016 and 2015.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements In accordance with the authoritative guidance for financial assets and liabilities measured at fair value on a recurring basis (ASC Topic 820), the Company prioritizes the inputs used to measure fair value from market-based assumptions to entity specific assumptions as follows: · Level 1—Inputs based on quoted market prices for identical assets or liabilities in active markets at the measurement date. · Level 2—Observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3—Inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instruments valuation. The following table presents the Company’s hierarchy for its assets measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015: Fair Value Measurements at June 30, 2016 Total Level 1 Level 2 Level 3 Assets: Current: Commercial paper $ 4,997 $ — $ 4,997 $ — Government sponsored securities 21,416 — 21,416 — Corporate debt securities 138,236 — 138,236 — Foreign government bonds 10,891 — 10,891 — Noncurrent: Government sponsored securities 27,188 — 27,188 — Corporate debt securities 80,745 — 80,745 — Total assets measured at fair value $ 283,473 $ — $ 283,473 $ — This table excludes $38.2 million in depository institutions that are classified as Level 1 assets. Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 18,039 $ — $ 18,039 $ — Commercial paper 24,917 — 24,917 — Corporate debt securities 86,450 — 86,450 — Foreign government bonds 6,943 — 6,943 — Noncurrent: Corporate debt securities 51,131 — 51,131 — Foreign government bonds 4,004 — 4,004 — Total assets measured at fair value $ 191,484 $ — $ 191,484 $ — *This amount excludes $157.9 million in depository institutions which are classified as Level 1 assets.

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	6. Commitments and Contingencies Contingencies In March 2009, the Company received a final rejection in one of the Company’s original patent applications pertaining to certain limited methods of use claims for NK-92 from the U.S. Patent and Trademark Office (the USPTO) (but the USPTO allowed claims on all of the other proposed claims, including other methods of use). The Company appealed this decision with the USPTO Board of Appeals and, in the fall of 2013, the Board of Appeals reversed the Examiner’s rejection of the claim to certain limited methods of use with NK-92, but affirmed the Examiner’s rejection of the remaining patent claims. In December 2013, the Company brought an action in the U.S. District Court for the Eastern District of Virginia to review the decision of the USPTO as the Company disagreed with the decision as to the certain limited non-allowed claims. On September 2, 2015, the U.S. District Court granted the USPTO’s motion for summary judgment. The Company is in the process of appealing the decision. Based on the information available at present, the Company cannot reasonably estimate a range of loss for this action. Accordingly, no liability associated with this action has been accrued. The Company is expensing legal costs associated with defending this litigation as the costs are incurred. Securities Litigation In March 2016, a securities class action complaint captioned Sudunagunta v. NantKwest, Inc., et al. Forsythe v. NantKwest, Inc., et al. In May 2016, the first of several complaints was filed in California Superior Court, Los Angeles County also related to the Company’s restatement of certain interim financial statements. Those complaints are captioned Wagner v. NantKwest, Inc., et al. Frye v. NantKwest, Inc., et al. Hare v. NantKwest, Inc. Wiencek v. NantKwest, Inc. et al. Contractual Obligations - Leases The Company leases: (i) office space in Cardiff-by-the-Sea, California; (ii) a research facility in Boston, Massachusetts on a month-to-month basis; (iii) a research facility in Woburn, Massachusetts (discussed further below) that replaced the Boston facility upon occupancy in May 2016; (iv) office space in Cary, North Carolina; (iv) a research facility in San Diego, California and; (v) research and manufacturing space in Culver City, California from a related party (Note 7). There were no new leases entered into during the three months ended June 30, 2016 In March 2016, the Company entered into a lease agreement for an approximately 7,893 square foot facility in Woburn, Massachusetts for a research and development laboratory, related office and other related uses. In June 2016, the lease was amended to add 260 square feet, for a total of 8,153 square feet. The base rent, including the amendment, is $0.2 million per year with a $1 per square foot annual increase on each anniversary date. The Company recognizes rent expense under its operating leases on a straight-line basis. Rent expense for the three months ended June 30, 2016 and 2015 was $0.7 million and $0.1 million, respectively, and $1.4 million and $0.2 million for the six months ended June 30, 2016 and 2015, respectively. Commitments The Company has not entered into any new significant contracts during the three months ended June 30, 2016.

Related Party Agreements

Related Party Agreements	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Agreements	7. Related Party Agreements The Company’s Chairman and CEO founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, the Company has entered into arrangements with NantWorks and certain affiliates of NantWorks to facilitate the development of new genetically modified NK cells for the Company’s product pipeline. In March 2016, NantBioScience, Inc. (NantBioScience), a NantWorks company, and the National Cancer Institute entered into a cooperative research and development agreement. The agreement covers NantBioScience and its affiliates, including the Company. Under the agreement, the parties will collaborate on the preclinical and clinical development of proprietary recombinant NK cells and monoclonal antibodies in monotherapy and in combination immunotherapies. The Company expects to benefit from the preclinical and clinical research conducted during the first year under this agreement and is providing the first year of funding under the five-year agreement. In April 2016, the Company paid $0.6 million to the National Cancer Institute as a prepayment for this first year of funding. The Company recognizes research and development expense ratably over a 12-month period and recorded $0.2 million as of June 30, 2016. Under the NantWorks shared services agreement executed in November 2015, but effective August 2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other support services, and the Company is charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. In June 2016, the Company amended the existing shared services agreement with NantWorks whereby the Company can provide such support services to NantWorks and/or any of its affiliates. For the three and six months ended June 30, 2016, the Company recorded $0.7 million and $1.5 million, respectively, to selling, general and administrative expense and $0.5 million and $0.8 million, respectively, to research and development expense under this arrangement on the condensed consolidated statement of operations. For the three months ended June 30, 2016, the Company recorded expense reimbursements of $9,000 to selling, general and administrative expense and $42,000 to research and development expense. No expenses were incurred during the three and six months ended June 30, 2015. The Company owed NantWorks a net amount of $1.7 million for all agreements between the two affiliates at June 30, 2016, which is included in due to related parties on the condensed consolidated balance sheet. Under the November 2015 facility license agreement with NantWorks for office and laboratory space, which was effective May 22, 2015, the Company recorded rent expense of $0.1 million and $0.3 million for the three and six months ended June 30, 2016, respectively, and $0.1 million for the three and six months ended June 30, 2015, which is included in research and development expense on the condensed consolidated statement of operations. The Company is responsible for costs to build out the laboratory and has incurred costs of approximately $3.5 million as of June 30, 2016, which is reflected in property and equipment, net on the condensed consolidated balance sheet. In addition, as the Company concluded that it was the “deemed owner” of the building (for accounting purposes only) during the construction period, the Company recorded a non-cash built-to-suit lease asset of $2.7 million representing its estimate of the fair market value of the building and a corresponding construction build-to-suit lease liability, recorded as a component of other current and non-current liabilities on the condensed consolidated balance sheet as of June 30, 2016. Under the June 2015 agreement with NantOmics, LLC (NantOmics) to obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics, the Company incurred $0

Spinout of Brink Biologics and

Spinout of Brink Biologics and Coneksis	6 Months Ended
	Jun. 30, 2016
Spinout
Spinout of Brink Biologics and Coneksis	8. Spinout of Brink Biologics and Coneksis On June 9, 2015, the Company spun out its business related to testing and diagnostic products and services into the entity, Brink Biologics, Inc. (Brink Biologics) in exchange for all of the issued and outstanding shares of Brink Biologics which were subsequently distributed by a dividend to the Company’s stockholders. Under the spin-out arrangement, the Company transferred to Brink Biologics all of the Company’s existing revenue-earning, non-exclusive license agreements that allow third parties to use the Company’s cell lines and intellectual property for non-clinical laboratory testing. In addition, the Company transferred or licensed to Brink Biologics the Company’s other assets associated with testing and diagnostics products and services. The Company granted to Brink Biologics worldwide, exclusive licenses to the use of certain cell lines limited to the field of in vitro in vivo On June 9, 2015, the Company spun out its business related to veterinary oncology into the entity, Coneksis in exchange for all of the issued and outstanding shares of Coneksis which were subsequently distributed by a dividend to our stockholders. In connection with the spin-out arrangement, the Company granted to Coneksis worldwide, exclusive licenses for use of certain cell lines in the field of veterinary medical research and therapeutics, trademarks, intellectual property, and patents, including the Company’s rights under its license agreement with Fox Chase Cancer Center. As part of the agreement, the Company also has a non-exclusive license to any results and data arising from Coneksis’ use of the Company’s cell lines and intellectual property for the Company’s use for internal research purposes and outside of Coneksis’ field. In consideration for the license grants, Coneksis is obligated to pay the Company a single-digit royalty on amounts received for the sale of licensed products and services, as well as a single-digit percentage share of other revenue received by Coneksis from the grant of sublicenses under the Company’s rights. Coneksis and the Company have the right to terminate the license agreement under certain conditions. Also, as part of the spin-out arrangement, the Company has agreed to provide certain services to Coneksis for a transitional period on a fee-for-service basis. For the three and six months ended June 30, 2016, the Company recorded $1,500 and $3,000, respectively, for services provided to Coneksis, which is included in other income on the condensed consolidated statement of operations. No charges were incurred for services from June 9, 2015 to June 30, 2015. At June 30, 2016, Coneksis owes the Company $9,000, which has been fully reserved. The Company determined it has a variable interest in Brink Biologics and Coneksis through its royalty agreements. Based upon the level of equity investment at risk, Brink Biologics and Coneksis are considered variable interest entities (VIEs). The Company considered whether it is the primary beneficiary of the Brink Biologics and Coneksis VIEs and required to consolidate the entities. As the Company does not control the research and development or the sales of the potential licensed or commercialized products, the Company does not direct the activities of Brink Biologics and Coneksis that most significantly impact their economic performance. Therefore, the Company determined that it is not the primary beneficiary of the entities and does not consolidate the Brink Biologics VIE and the Coneksis VIE.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Stock Repurchase— In November 2015, the board of directors approved a share repurchase program (2015 Share Repurchase Program) allowing the CEO or CFO, on behalf of the Company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0 million of the Company’s outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases will be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company expects to finance the purchases with existing cash balances. During the three and six months ended June 30, 2016, the Company repurchased 928,600 and 1,228,600 shares of its common stock, respectively, at prices ranging between $6.05 per share and $8.50 per share for a total of $9.3 million. The shares were formally retired through board approval on June 15, 2016. The Company incurred approximately $28,000 of broker commissions on the repurchases. The Company accounted for the repurchases under the constructive retirement method and allocated the excess of the repurchase price over par value to accumulated deficit. At June 30, 2016, $40.7 million remained authorized for repurchase under the Company’s 2015 Share Repurchase Program. A summary of common stock repurchases for the six months ended June 30, 2016 is as follows: Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Maximum approximate dollar value of shares that may yet be purchased under the plans or programs February 300,000 $ 8.50 300,000 $47.5 million May 346,200 $ 6.77 646,200 $45.1 million June 582,400 $ 7.56 1,228,600 $40.7 million Total 1,228,600 $ 7.57

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation Stock-Based Compensation The following table presents stock-based compensation included on the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (Restated) (Restated) Stock-based compensation expense: Warrants for Class A common stock to an officer $ 15,182 $ 122,190 $ 27,272 $ 122,190 Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition — — — 22,747 Employee stock options 4,858 2,521 9,751 3,609 Non-employee stock options — 1,602 — 2,290 Employee restricted stock units 3,148 — 6,530 — Non-employee restricted stock units 167 — 364 — $ 23,355 $ 126,313 $ 43,917 $ 150,836 Stock-based compensation expense in operating expenses: Research and development 291 $ 587 $ 564 $ 776 Selling, general and administrative 23,064 125,726 43,353 150,060 $ 23,355 $ 126,313 $ 43,917 $ 150,836 In the second quarter of 2016, the Company adopted ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ASU 2016-09 also requires the recognition of the income tax effects of awards in the condensed consolidated statement of operations when the awards vest or are settled, thus eliminating addition paid-in capital pools. The Company elected to adopt the amendments related to the presentation of excess tax benefits on the condensed consolidated statement of cash flows using a prospective transition method. Stock Options The following table summarizes stock option activity under the equity incentive plans for the six months ended June 30, 2016 (in thousands, except for share and per share amounts): Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2015 8,777,893 $ 5.36 $ 116,273 7.2 Options forfeited (71,627 ) $ 2.00 Options exercised (1,642,264 ) $ 0.78 Outstanding at June 30, 2016 7,064,002 $ 6.45 $ 25,677 6.4 Vested and Exercisable at June 30, 2016 4,480,534 The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2016 was $11.9 million. The total unrecognized compensation cost related to non-vested stock options as of June 30, 2016 is $14.0 million, which is expected to be recognized over a weighted-average period of 2.2 years. Restricted Stock Units The following table summarizes the activity for restricted stock units under the 2015 Plan: Number of Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value Unvested balance at December 31, 2015 1,129,638 $ 20.51 Granted 407,800 $ 7.76 Vested (24,166 ) $ 9.95 Forfeited (88,500 ) $ 12.07 Unvested balance at June 30, 2016 1,424,772 $ 17.73 During the six months ended June 30, 2016, the Company granted restricted stock units of 407,800 shares of common stock, of which 340,300 were granted to employees of the Company and 67,500 were granted to employees of related companies under the Company’s shared services agreement with NantWorks (Note 7). As of June 30, 2016, there was $8.8 million of unrecognized stock-based compensation expense related to restricted stock units that is expected to be recognized over a weighted-average period of 1.8 years. Of that amount, $6.5 million of unrecognized expense is related to employee grants with a weighted-average period of 1.3 year and $2.3 million of unrecognized expense is related to non-employee grants with a weighted-average period of 3.3 years and is impacted by periodic mark-to-market adjustments. Warrants The following table summarizes the warrant activity for the six months ended June 30, 2016: Outstanding at December 31, 2015 17,819,616 Warrants exercised (25,072 ) Outstanding at June 30, 2016 17,794,544 Vested and exercisable at June 30, 2016 11,109,000 The total unrecognized compensation cost related to non-vested warrants as of June 30, 2016 is $72.6 million, which is expected to be recognized over a weighted-average period of 2.0 years.

Acquisition of Inex Bio, Inc

Acquisition of Inex Bio, Inc	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Acquisition of Inex Bio, Inc	11. Acquisition of Inex Bio, Inc. In April 2012, the Company made a strategic decision to enter into a License Agreement with Inex Bio, Inc. (Inex Bio), a Republic of Korea corporation (the Inex License Agreement). Under the Inex License Agreement, the Company provided Inex Bio with an exclusive license to the Company’s technology to be used in products only in certain Asian countries. In exchange for the Inex License Agreement, the Company received a $0.3 million up-front license fee. In addition, the Company was eligible to receive milestone payments of up to $0.8 million based upon completion of clinical trials and a 5% royalty on net sales of applicable products using the aNK cells. No milestone payments were due or received for the three months ended March 31, 2015, the quarter in which the Company completed its acquisition of Inex Bio, as further discussed below. In May 2012, the Company acquired 57,000 shares of Inex Bio for $0.2 million, which represented 22.2% of the outstanding shares and 17.4% of the fully-diluted shares of Inex Bio. The Company accounted for its investment under the equity method. The Company reviewed its investment for impairment in accordance with ASC Topic 320, Investments—Debt and Equity Securities. In February and March 2015, InexBio Holdings, LLC (Holdings), an entity owned 50% by Cambridge Equities, L.P., an entity in which the Company’s CEO is the sole member of its general partner, and 50% Eragon Ventures, LLC, an entity of which one of the Company’s former directors is managing member, acquired 220,000 shares or 67.3% of Inex Bio from third party owners for $1.1 million. On March 30, 2015, the Company entered into a Stock Purchase Agreement with Holdings and the third party owners, pursuant to which the Company acquired all the remaining outstanding shares of Inex Bio not previously held by the Company. The Company paid to the other owners of Inex Bio cash of $1.5 million and issued warrants to acquire 593,072 shares of the Company’s Class A common stock at an exercise price of $2.00 per share. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. This resulted in a total fair value of the warrants of $5.2 million. In April 2015, the Company received $1.2 million for the full exercise of the warrants. The Company recorded the transaction as an asset purchase because Inex Bio was a shell corporation without any employees or other significant assets and it did not meet the definition of a business under ASC Topic 805, Business Combinations. The purchase price paid to acquire Inex Bio from the other owners is as follows (in thousands): Consideration Total Cash paid by InexBio Holdings, LLC $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752 The following table summarizes the assets acquired and liabilities assumed (in thousands): Cash $ 763 Intangible assets—reacquired rights of Company technology* 8,636 Other assets 42 Investment in Inex Bio (221 ) Deferred tax liability (1,467 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752 * Inclusive of $1.5 million intangible asset related to deferred tax liability. The license solely covers pending patent applications at this time. The Company amortizes the intangible assets over 4 years, which represents the period until the next action date of the pending patent application in the territory of the license issued to Inex Bio. The Company paid Holdings cash of $6.5 million and issued warrants to acquire 2,609,520 shares of the Company’s Class A common stock at an exercise price of $2.00 per share for its assistance in negotiating the acquisition of Inex Bio from the other owners. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. This resulted in a fair value of total warrants of $22.7 million. In April 2015, the Company received $5.2 million for the full exercise of the warrants. The following summarizes the net consideration paid to Holdings (in thousands): Consideration Total Cash $ 6,518 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,165 The Company recorded compensation expense for the portion of the cash and warrants issued to Holdings that exceeded the fair value of the shares acquired consistent with ASC Topic 718. The Company recorded $22.7 million of stock-based compensation and $5.4 million of cash compensation to the Company’s chief executive officer and the former director as a result of acquiring their interest in Inex Bio.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The difference between the federal statutory tax rate of 34% and the Company’s 0% tax rate is due to losses in jurisdictions from which the Company cannot benefit. Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. The Company then records a related tax benefit in continuing operations. During the six months ended June 30, 2016, the Company recorded unrealized gains on its marketable securities in other comprehensive income, net of taxes. As a result, for the six months ended June 30, 2016 and 2015, the Company recorded a $0.2 million and $0 tax benefit, respectively, on the condensed consolidated statement of operations and $0.4 million and $0, respectively, in other comprehensive income. The Company is operating in Korea. During the six months ended June 30, 2016 and 2015, the tax benefit related to Korea is $0.2 million and $0, respectively. The Company currently files federal and state income tax returns in the United States and in Korea. Income tax expense consists of U.S. federal, state, and Korean income taxes. To date, the Company has not been required to pay U.S. federal income taxes because of current and accumulated net operating losses. Under ASU 2016-09, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) should be recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefits reduce tax payable in the current period. The Company made an early adoption on the ASU 2016-09 effect in the second quarter of 2016. There is no cumulative impact as the federal excess deduction recognition of $40,000 and the state excess deduction recognition of $34,000 are offset by a corresponding change to the valuation allowance. The current year excess benefit of $6.2 million is offset by a corresponding change in the valuation allowance.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc., and have been prepared in accordance with GAAP. All intercompany amounts have been eliminated.
Liquidity	Liquidity As of June 30, 2016, the Company had an accumulated deficit of approximately $324.4 million. The Company also had negative cash flow from operations of approximately $17.2 million during the six months ended June 30, 2016. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents and marketable securities on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents and marketable securities will enable it to fund operations and capital expenditure requirements for the foreseeable future, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Preclinical and Clinical Trial Accruals	Preclinical and As part of the process of preparing the financial statements, the Company is required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company estimates clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on the Company’s behalf. In accruing clinical and research related fees, the Company estimates the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
Stock Repurchases	Stock Repurchases In November 2015, the board of directors approved a share repurchase program (2015 Share Repurchase Program) allowing the CEO or CFO, on behalf of the Company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0 million of the Company’s outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases will be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company expects to finance the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, the Company has elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, the Company will allocate the excess value to accumulated deficit.
Stock-Based Compensation	Stock-Based Compensation The Company implemented Financial Accounting Standards Board issued Accounting Standard Update 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, preclinical and clinical trial accruals, and the valuation of build-to-suit lease assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Basic and Diluted Net Loss Per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of June 30, 2016 2015 Outstanding options 7,064,002 8,447,209 Outstanding restricted stock units 1,424,772 — Outstanding warrants 17,794,544 18,417,078 Total 26,283,318 26,864,287 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued or ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting The Company has adopted the guidance to 1) account for stock-based award forfeitures as they occur rather than apply an estimated forfeiture rate, 2) recognize the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid-in capital pools, 3) repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, and 4) elected to adopt the amendments related to the presentation of excess tax benefits on the statement of cash flows using a prospective transition method.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Securities Excluded from the Computation of Potentially Dilutive Securities	The following table details those securities that have been excluded from the computation of potentially dilutive securities: As of June 30, 2016 2015 Outstanding options 7,064,002 8,447,209 Outstanding restricted stock units 1,424,772 — Outstanding warrants 17,794,544 18,417,078 Total 26,283,318 26,864,287 Amounts in the table above reflect the common stock equivalents of the noted instruments.

Financial Statement Details (Ta

Financial Statement Details (Tables)	6 Months Ended
	Jun. 30, 2016
Financial Statement Details [Abstract]
Receivables, Net, Prepaid Expenses and Other Current Assets	As of June 30, 2016 and December 31, 2015, receivables, net, prepaid expenses and other current assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Prepaid services $ 1,537 $ 631 Interest receivable - marketable securities 1,428 911 Prepaid license fees 475 101 Prepaid legal fees 350 350 Deposits 141 — Due from related parties (Note 7) 121 217 Prepaid insurance 84 466 Prepaid rent 46 — Accounts receivable, net 3 — Tax refund receivable — 646 Other 11 — $ 4,196 $ 3,322
Property and Equipment	As of June 30, 2016 and December 31, 2015, property and equipment consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Construction in progress $ 7,825 $ 5,136 Equipment 1,021 241 Software 400 6 Leasehold improvements 356 182 Furniture & fixtures 175 125 9,777 5,690 Accumulated depreciation (270 ) (167 ) $ 9,507 $ 5,523
Intangible Assets	As of June 30, 2016 and December 31, 2015, intangible assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Technology license* $ 8,636 $ 8,636 Less accumulated amortization (2,240 ) (1,344 ) $ 6,396 $ 7,292 *Inclusive of $1.5 million intangible asset related to the deferred tax liability, which is not amortized.
Other Assets	As of June 30, 2016 and December 31, 2015, other assets consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Equipment not placed in service $ 567 $ 624 License fees 308 — Security deposit 248 344 Software license and implementation costs 17 391 $ 1,140 $ 1,359
Accrued Expenses	As of June 30, 2016 and December 31, 2015, accrued expenses consisted of (in thousands): June 30, 2016 December 31, 2015 (Unaudited) Accrued bonus $ 2,179 $ 1,359 Accrued professional and service fees 616 367 Accrued construction costs 610 132 Accrued compensation 590 348 Accrued preclinical and clinical trial costs 449 — Accrued trade shows 109 — Accrued franchise and property taxes 39 225 Other 132 144 $ 4,724 $ 2,575
Investment Income, Net	Net investment income includes interest income from all bank accounts as well as marketable securities, net realized gains or losses on sales of investments and the amortization of the premiums and discounts of the investments and is as follows for the three and six months ended June 30, 2016 and 2015 (in thousands). Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Interest income $ 1,239 $ 33 $ 2,431 $ 65 Investment amortization accretion expense, net (516 ) — (942 ) — Net realized gains on investments 16 — 18 — $ 739 $ 33 $ 1,507 $ 65

Cash Equivalents and Marketab23

Cash Equivalents and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2016
Cash Equivalents And Marketable Securities [Abstract]
Schedule of Cash Equivalents and Marketable Securities Available-for-Sale	At June 30, 2016, the detail of the Company’s cash equivalents and marketable securities is as follows (in thousands): June 30, 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current: Commercial paper $ 4,993 $ 4 $ — $ 4,997 Government sponsored securities 21,384 32 — 21,416 Corporate debt securities 138,173 80 (17 ) 138,236 Foreign government bonds 10,880 13 (2 ) 10,891 Current portion 175,430 129 (19 ) 175,540 Noncurrent: Government sponsored securities 27,022 166 — 27,188 Corporate debt securities 80,241 510 (6 ) 80,745 Noncurrent portion 107,263 676 (6 ) 107,933 Total $ 282,693 $ 805 $ (25 ) $ 283,473
Available-for-Sale Investments in Unrealized Loss Position	Available-for-sale investments that had been in an unrealized loss position for less than 12 months at June 30, 2016 are as follows (in thousands): June 30, 2016 Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 60,926 $ (23 ) Foreign government bonds 1,864 (2 ) Total $ 62,790 $ (25 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015: Fair Value Measurements at June 30, 2016 Total Level 1 Level 2 Level 3 Assets: Current: Commercial paper $ 4,997 $ — $ 4,997 $ — Government sponsored securities 21,416 — 21,416 — Corporate debt securities 138,236 — 138,236 — Foreign government bonds 10,891 — 10,891 — Noncurrent: Government sponsored securities 27,188 — 27,188 — Corporate debt securities 80,745 — 80,745 — Total assets measured at fair value $ 283,473 $ — $ 283,473 $ — This table excludes $38.2 million in depository institutions that are classified as Level 1 assets. Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents* $ 18,039 $ — $ 18,039 $ — Commercial paper 24,917 — 24,917 — Corporate debt securities 86,450 — 86,450 — Foreign government bonds 6,943 — 6,943 — Noncurrent: Corporate debt securities 51,131 — 51,131 — Foreign government bonds 4,004 — 4,004 — Total assets measured at fair value $ 191,484 $ — $ 191,484 $ — *This amount excludes $157.9 million in depository institutions which are classified as Level 1 assets.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Common Stock Repurchases	A summary of common stock repurchases for the six months ended June 30, 2016 is as follows: Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Maximum approximate dollar value of shares that may yet be purchased under the plans or programs February 300,000 $ 8.50 300,000 $47.5 million May 346,200 $ 6.77 646,200 $45.1 million June 582,400 $ 7.56 1,228,600 $40.7 million Total 1,228,600 $ 7.57

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation Expenses Included in Operations Statement	The following table presents stock-based compensation included on the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (Restated) (Restated) Stock-based compensation expense: Warrants for Class A common stock to an officer $ 15,182 $ 122,190 $ 27,272 $ 122,190 Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition — — — 22,747 Employee stock options 4,858 2,521 9,751 3,609 Non-employee stock options — 1,602 — 2,290 Employee restricted stock units 3,148 — 6,530 — Non-employee restricted stock units 167 — 364 — $ 23,355 $ 126,313 $ 43,917 $ 150,836 Stock-based compensation expense in operating expenses: Research and development 291 $ 587 $ 564 $ 776 Selling, general and administrative 23,064 125,726 43,353 150,060 $ 23,355 $ 126,313 $ 43,917 $ 150,836
Summarizes Stock Option Activity Under Equity Intensive Plan	The following table summarizes stock option activity under the equity incentive plans for the six months ended June 30, 2016 (in thousands, except for share and per share amounts): Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2015 8,777,893 $ 5.36 $ 116,273 7.2 Options forfeited (71,627 ) $ 2.00 Options exercised (1,642,264 ) $ 0.78 Outstanding at June 30, 2016 7,064,002 $ 6.45 $ 25,677 6.4 Vested and Exercisable at June 30, 2016 4,480,534
Restricted Stock Units Activity	The following table summarizes the activity for restricted stock units under the 2015 Plan: Number of Restricted Stock Units Outstanding Weighted-Average Grant Date Fair Value Unvested balance at December 31, 2015 1,129,638 $ 20.51 Granted 407,800 $ 7.76 Vested (24,166 ) $ 9.95 Forfeited (88,500 ) $ 12.07 Unvested balance at June 30, 2016 1,424,772 $ 17.73
Summary of Warrant Activity	The following table summarizes the warrant activity for the six months ended June 30, 2016: Outstanding at December 31, 2015 17,819,616 Warrants exercised (25,072 ) Outstanding at June 30, 2016 17,794,544 Vested and exercisable at June 30, 2016 11,109,000

Acquisition of Inex Bio, Inc (T

Acquisition of Inex Bio, Inc (Tables)	6 Months Ended
	Jun. 30, 2016
Summary of Purchase Price Paid to Inex Bio	The following summarizes the net consideration paid to Holdings (in thousands): Consideration Total Cash $ 6,518 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,165
Summary of Assets and Liabilities Assumed	The following table summarizes the assets acquired and liabilities assumed (in thousands): Cash $ 763 Intangible assets—reacquired rights of Company technology* 8,636 Other assets 42 Investment in Inex Bio (221 ) Deferred tax liability (1,467 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752 * Inclusive of $1.5 million intangible asset related to deferred tax liability.
Inex Bio Inc
Summary of Purchase Price Paid to Inex Bio	The purchase price paid to acquire Inex Bio from the other owners is as follows (in thousands): Consideration Total Cash paid by InexBio Holdings, LLC $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752

Description of Business and B28

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jan. 01, 2016	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ (324,405)		$ 31,000	$ (250,376)
Net cash used in operating activities	$ (17,157)	$ (10,162)

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail)	Nov. 30, 2015USD ($)
Equity [Abstract]
Total amount authorized for repurchase	$ 50,000,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	26,283,318	26,864,287
Employee Stock Option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,064,002	8,447,209
Outstanding Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,424,772
Outstanding Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	17,794,544	18,417,078

Financial Statement Details - R

Financial Statement Details - Receivables, Net, Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Prepaid services	$ 1,537	$ 631
Interest receivable - marketable securities	1,428	911
Prepaid license fees	475	101
Prepaid legal fees	350	350
Deposits	141
Due from related parties (Note 7)	121	217
Prepaid insurance	84	466
Prepaid rent	46
Accounts receivable, net	3
Tax refund receivable		646
Other	11
Total receivables, net, prepaid expenses and other current assets	$ 4,196	$ 3,322

Financial Statement Details - P

Financial Statement Details - Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 9,777	$ 5,690
Accumulated depreciation	(270)	(167)
Property and equipment, net	9,507	5,523
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,825	5,136
Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,021	241
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	400	6
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	356	182
Furniture And Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 175	$ 125

Financial Statement Details - A

Financial Statement Details - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Financial Statement Details [Line Items]
Impairment losses on recognized investments	$ 0	$ 0	$ 0	$ 0
Technology License
Financial Statement Details [Line Items]
Amortization expense	500,000	$ 400,000	900,000	$ 400,000
NantWorks
Financial Statement Details [Line Items]
Non cash build to suit lease asset	$ 2,700,000		$ 2,700,000

Financial Statement Details - I

Financial Statement Details - Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Finite Lived Intangible Assets [Line Items]
Intangible assets, net	$ 6,396	$ 7,292
Technology License
Finite Lived Intangible Assets [Line Items]
Total intangible assets	8,636	8,636
Less accumulated amortization	(2,240)	(1,344)
Intangible assets, net	$ 6,396	$ 7,292

Financial Statement Details -35

Financial Statement Details - Intangible Assets (Parenthetical) (Detail) $ in Millions	Jun. 30, 2016USD ($)
Technology License
Finite Lived Intangible Assets [Line Items]
Intangible asset related to deferred tax liability	$ 1.5

Financial Statement Details - O

Financial Statement Details - Other Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Equipment not placed in service	$ 567	$ 624
License fees	308
Security deposit	248	344
Software license and implementation costs	17	391
Other Assets Noncurrent	$ 1,140	$ 1,359

Financial Statement Details -37

Financial Statement Details - Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Financial Statement Details [Abstract]
Accrued bonus	$ 2,179	$ 1,359
Accrued professional and service fees	616	367
Accrued construction costs	610	132
Accrued compensation	590	348
Accrued preclinical and clinical trial costs	449
Accrued trade shows	109
Accrued franchise and property taxes	39	225
Other	132	144
Accrued Liabilities Current	$ 4,724	$ 2,575

Financial Statement Details -38

Financial Statement Details - Investment Income, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Financial Statement Details [Abstract]
Interest income	$ 1,239	$ 33	$ 2,431	$ 65
Investment amortization accretion expense, net	(516)		(942)
Net realized gains on investments	16		18
Investment income, net	$ 739	$ 33	$ 1,507	$ 65

Cash Equivalents and Marketab39

Cash Equivalents and Marketable Securities - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016Security
Schedule Of Available For Sale Securities [Line Items]
Available for sale securities maturity period	4 years
Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Number of available-for-sale securities in unrealized loss positions	29
Maximum
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, period of unrealized loss positions	12 months

Cash Equivalents and Marketab40

Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities Available-for-Sale (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 282,693
Unrealized Gains	805
Unrealized Losses	(25)
Fair Value	283,473
Current Assets
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	175,430
Unrealized Gains	129
Unrealized Losses	(19)
Fair Value	175,540
Current Assets | Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,993
Unrealized Gains	4
Fair Value	4,997
Current Assets | Government Sponsored Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	21,384
Unrealized Gains	32
Fair Value	21,416
Current Assets | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	138,173
Unrealized Gains	80
Unrealized Losses	(17)
Fair Value	138,236
Current Assets | Foreign Government Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	10,880
Unrealized Gains	13
Unrealized Losses	(2)
Fair Value	10,891
Noncurrent Assets
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	107,263
Unrealized Gains	676
Unrealized Losses	(6)
Fair Value	107,933
Noncurrent Assets | Government Sponsored Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	27,022
Unrealized Gains	166
Fair Value	27,188
Noncurrent Assets | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	80,241
Unrealized Gains	510
Unrealized Losses	(6)
Fair Value	$ 80,745

Cash Equivalents and Marketab41

Cash Equivalents and Marketable Securities - Available-for-Sale Investments in Unrealized Loss Position (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	$ 62,790
Available for Sale Investments, Gross Unrealized Losses	(25)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	60,926
Available for Sale Investments, Gross Unrealized Losses	(23)
Foreign Government Bonds
Schedule Of Available For Sale Securities [Line Items]
Available for Sale Investments, Estimated Fair Value	1,864
Available for Sale Investments, Gross Unrealized Losses	$ (2)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 283,473	$ 191,484
Current Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	10,891	6,943
Current Assets | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,997	24,917
Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	138,236	86,450
Current Assets | Cash and cash equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value		18,039
Current Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	21,416
Noncurrent Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value		4,004
Noncurrent Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	80,745	51,131
Noncurrent Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	27,188
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	283,473	191,484
Level 2 | Current Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	10,891	6,943
Level 2 | Current Assets | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	4,997	24,917
Level 2 | Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	138,236	86,450
Level 2 | Current Assets | Cash and cash equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value		18,039
Level 2 | Current Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	21,416
Level 2 | Noncurrent Assets | Foreign Government Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value		4,004
Level 2 | Noncurrent Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	80,745	$ 51,131
Level 2 | Noncurrent Assets | Government Sponsored Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 27,188

Fair Value Measurements - Sum43

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash in depository institutions	$ 38.2	$ 157.9

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)ft²Lease$ / ft²	Jun. 30, 2016USD ($)ft²Lease	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)ft²Lease	Jun. 30, 2015USD ($)	Mar. 31, 2016ft²
Commitments And Contingencies [Line Items]
Number of new leases entered during period | Lease	0	0		0
Rent expense | $		$ 0.7	$ 0.1	$ 1.4	$ 0.2
Woburn, Massachusetts
Commitments And Contingencies [Line Items]
Number of square foot of facility leased. | ft²	8,153	8,153		8,153		7,893
Addition to number of square foot of facility leased | ft²	260	260		260
Base rent - yearly | $	$ 0.2
Annual increase of base rent | $ / ft²	1
Period of agreement				In June 2016, the lease was amended to add 260 square feet, for a total of 8,153 square feet. The base rent, including the amendment, is $0.2 million per year with a $1 per square foot annual increase on each anniversary date.

Related Party Agreements - Addi

Related Party Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Research and development		$ 6,389,000	$ 2,074,000	$ 11,344,000	$ 2,677,000
Selling, general and administrative		28,588,000	128,412,000	55,255,000	160,030,000
Due to related parties		1,727,000		1,727,000		$ 1,352,000
NantBioScience
Related Party Transaction [Line Items]
Research and development	$ 600,000			$ 200,000
Research and development expense, ratable payment period				12 months
NantWorks
Related Party Transaction [Line Items]
Due to related parties		1,700,000		$ 1,700,000
Costs incurred		3,500,000		3,500,000
Non cash build to suit lease asset		2,700,000		2,700,000
NantWorks | Research and Development
Related Party Transaction [Line Items]
Rent expense		100,000	100,000	300,000	100,000
NantWorks | Shared Services Agreement
Related Party Transaction [Line Items]
Research and development		500,000		800,000	0
NantWorks | Reimbursements | Shared Services Agreement
Related Party Transaction [Line Items]
Research and development		42,000,000	0		0
NantWorks | As Adjusted | Shared Services Agreement
Related Party Transaction [Line Items]
Selling, general and administrative		700,000		1,500,000	0
NantWorks | As Adjusted | Reimbursements | Shared Services Agreement
Related Party Transaction [Line Items]
Selling, general and administrative		9,000,000	0		$ 0
NantOmics
Related Party Transaction [Line Items]
Research and development		$ 0	$ 0	$ 100,000
Initial term of agreement entered into with the related party by the entity				5 years
Related party, agreement renewal term				1 year

Spinout of Brink Biologics an46

Spinout of Brink Biologics and Coneksis - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Amount owed to the company	$ 121	$ 121	$ 217
Brink Biologics Inc | Spinout
Related Party Transaction [Line Items]
Royalty revenue	6,000	7,000
Revenue from services	7,000	14,000
Amount owed to the company	100	100
Coneksis | Spinout
Related Party Transaction [Line Items]
Revenue from services	1,500	3,000
Amount owed to the company	$ 9,000	$ 9,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2016	Nov. 30, 2015
Class Of Stock [Line Items]
Total amount authorized for repurchase						$ 50,000,000
Repurchase of common stock, shares	582,400	346,200	300,000	928,600	1,228,600
Repurchase of common stock, par value	$ 7.56	$ 6.77	$ 8.50		$ 7.57
Repurchase of common stock, value	$ 1,228,600	$ 646,200	$ 300,000		$ 9,324,000
Remained authorized shares for repurchase	$ 40,700,000	$ 45,100,000	$ 47,500,000	$ 40,700,000	40,700,000
Broker commissions on the repurchases					$ 28,000,000
Minimum
Class Of Stock [Line Items]
Repurchase of common stock, par value					$ 6.05
Maximum
Class Of Stock [Line Items]
Repurchase of common stock, par value					$ 8.50

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Common Stock Repurchases (Detail) - USD ($)	1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2016
Equity [Abstract]
Repurchase of common stock, shares	582,400	346,200	300,000	928,600	1,228,600
Repurchase of common stock, par value	$ 7.56	$ 6.77	$ 8.50		$ 7.57
Repurchase of common stock, value	$ 1,228,600	$ 646,200	$ 300,000		$ 9,324,000
Remained authorized shares for repurchase	$ 40,700,000	$ 45,100,000	$ 47,500,000	$ 40,700,000	$ 40,700,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 23,355	$ 126,313	$ 43,917	$ 150,836
Warrants For Class A Common Stock | Officer
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	15,182	122,190	27,272	122,190
Warrants For Class A Common Stock | Director Related to Inex Bio, Inc
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense				22,747
Employee Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	4,858	2,521	9,751	3,609
Non Employee Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		1,602		2,290
Employee Restricted Stock Units | Employees Of Related Company
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,148		6,530
Non Employee Restricted Stock Units
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	167		364
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	291	587	564	776
Selling, General and Administrative | Employee And Non Employee
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 23,064	$ 125,726	$ 43,353	$ 150,060

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Jun. 30, 2016	Jan. 01, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Accumulated deficit		$ (324,405)	$ 31,000	$ (250,376)
Additional stock compensation expense	$ 27,000
Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average period for recognition		2 years
Unrecognized compensation cost related to non-vested warrants		$ 72,600
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised		11,900
Unrecognized compensation cost related to non-vested stock options		$ 14,000
Weighted-average period for recognition		1 year 4 months 24 days
Outstanding Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options		$ 8,800
Weighted-average period for recognition		1 year 7 months 6 days
Number of Shares, Granted		407,800
Outstanding Restricted Stock Units | Employees Of Related Company
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted		67,500
Employee Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options		$ 6,500
Weighted-average period for recognition		1 year
Number of Shares, Granted		340,300
Non Employee Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options		$ 2,300
Weighted-average period for recognition		3 years 3 months 18 days

Stock-Based Compensation - St51

Stock-Based Compensation - Stock Option Activity (Detail) - Employee Stock Option - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Number of Shares
Stock Options, Beginning Balance	8,777,893
Stock Options, Options forfeited	(71,627)
Stock Options, Options exercised	(1,642,264)
Stock Options, Ending Balance	7,064,002	8,777,893
Stock Options, Vested and Exercisable	4,480,534
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning balance	$ 5.36
Weighted Average Exercise Price, Options forfeited	2
Weighted Average Exercise Price, Options exercised	0.78
Weighted Average Exercise Price, Outstanding Ending balance	$ 6.45	$ 5.36
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 25,677	$ 116,273
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	6 years 4 months 24 days	7 years 2 months 12 days

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Detail) - Outstanding Restricted Stock Units	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested, Beginning balance | shares	1,129,638
Number of Shares, Granted | shares	407,800
Number of Shares, Vested | shares	(24,166)
Number of Shares, Forfeited | shares	(88,500)
Number of Shares, Unvested, Ending balance | shares	1,424,772
Weighted-Average Grant Date Fair Value, Unvested, beginning balance | $ / shares	$ 20.51
Weighted-Average Grant Date Fair Value, Granted | $ / shares	7.76
Weighted-Average Grant Date Fair Value, Vested | $ / shares	9.95
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	12.07
Weighted-Average Grant Date Fair Value, Unvested, ending balance | $ / shares	$ 17.73

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Warrant Activity (Detail) - Outstanding Warrants	6 Months Ended
	Jun. 30, 2016shares
Warrant [Line Items]
Warrants, Beginning Balance	17,819,616
Warrants exercised	(25,072)
Warrants, Ending Balance	17,794,544
Warrants, Vested and exercisable Ending Balance	11,109,000

Acquisition of Inex Bio, Inc -

Acquisition of Inex Bio, Inc - Additional Information (Detail) - USD ($)	Mar. 30, 2015	Apr. 30, 2015	May 31, 2012	Apr. 30, 2012	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Asset Purchase [Line Items]
Number of shares acquired during period			57,000
Stock issued during period, value, acquisitions			$ 200,000
Outstanding shares acquired, percentage			22.20%
Percentage of fully diluted shares acquired			17.40%
Proceeds from exercise of warrants						$ 41,000	$ 7,134,000
Stock-based compensation expense						43,917,000	$ 150,836,000
Inex Bio Holdings, LLC
Asset Purchase [Line Items]
Payments to acquire business						6,500,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Issuance of warrants in Inex Bio acquisition						22,747,000
Stock-based compensation expense						22,700,000
Cash based compensation						$ 5,400,000
Inex Bio Holdings, LLC | Common Class A
Asset Purchase [Line Items]
Warrants issued to acquire shares						2,609,520
Common stock exercise price						$ 2
Proceeds from exercise of warrants		$ 5,200,000
Other Owner Of Inex Bio Inc
Asset Purchase [Line Items]
Payments to acquire business					$ 1,500,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Issuance of warrants in Inex Bio acquisition						$ 5,170,000
Other Owner Of Inex Bio Inc | Common Class A
Asset Purchase [Line Items]
Warrants issued to acquire shares					593,072
Common stock exercise price					$ 2
Proceeds from exercise of warrants		$ 1,200,000
Inex Bio
Asset Purchase [Line Items]
Intangible assets amortizes period						4 years
Cambridge Equities, L.P | Inex Bio Holdings, LLC
Asset Purchase [Line Items]
Ownership percentage of third party business					50.00%
Eragon Ventures, LLC
Asset Purchase [Line Items]
Number of shares acquired during period					220,000
Ownership percentage of third party business					50.00%
Percentage shares acquired					67.30%
Payments to acquire business					$ 1,100,000
Inex license agreement
Asset Purchase [Line Items]
Milestone payment amount					$ 0
Percentage of royalty on net sales				5.00%
Up front fee | Inex license agreement
Asset Purchase [Line Items]
License fees received				$ 300,000
Maximum | Inex license agreement
Asset Purchase [Line Items]
Milestone payment amount				$ 800,000

Acquisition of Inex Bio, Inc 55

Acquisition of Inex Bio, Inc - Summary of Purchase Price Paid to Inex Bio (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Asset Purchase [Line Items]
Cash paid by InexBio Holdings, LLC	$ 1,100
Cash paid by Company	1,482
Fair value of warrants	5,170
Aggregate purchase price	$ 7,752

Acquisition of Inex Bio, Inc 56

Acquisition of Inex Bio, Inc - Summary of Assets and Liabilities Assumed (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	Jun. 30, 2016USD ($)
Asset Purchase [Line Items]
Cash	$ 763
Intangible assets—reacquired rights of Company technology	8,636
Other assets	42
Investment in Inex Bio	(221)
Deferred tax liability	(1,467)
Accounts payable	(1)
Total assets acquired and liabilities assumed	$ 7,752

Acquisition of Inex Bio, Inc 57

Acquisition of Inex Bio, Inc - Summary of Assets and Liabilities Assumed (Parenthetical) (Detail) $ in Millions	Jun. 30, 2016USD ($)
Technology License
Asset Purchase [Line Items]
Intangible asset related to deferred tax liability	$ 1.5

Acquisition of Inex Bio, Inc 58

Acquisition of Inex Bio, Inc - Summary of Net Consideration Paid to Holdings (Detail) - Inex Bio Holdings, LLC $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Asset Purchase [Line Items]
Cash	$ 6,518
Fair value of warrants	22,747
Less cash paid to acquire shares in Inex Bio	(1,100)
Aggregate purchase price	$ 28,165

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Income Tax [Line Items]
Federal statutory tax rate	34.00%
Company's effective tax rate	0.00%
Tax benefit	$ 200,000	$ 0
Tax benefit in other comprehensive income	400,000	0
ASU 2016-09
Income Tax [Line Items]
Federal excess deduction tax amount	40,000,000
State excess deduction tax amount	34,000,000
Total current year benefit	(6,200,000)
Korea
Income Tax [Line Items]
Tax benefit	$ 200,000	$ 0